Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries

Mahil, S; Schaefer, M; Dand, N; Yiu, Z; Hyrich, K; Strangfeld, A; Yates, M; Carmona, L; Gossec, L; Mateus, E; Lawson-Tovey, S; Wiek, D; Jacobsohn, L; Isnardi, C; Quintana, R; Soriano, E; Wallace, Z; Bhana, S; Gore-Massey, M; Grainger, R; Hausmann, J; Liew, J; Sirotich, E; Mason, K; Tsakok, T; Meynell, F; Coker, B; Vincent, A; Urmston, D; Mcateer, H; Vesty, A; Kelly, J; Lancelot, C; Moorhead, L; Mackenzie, T; Rossi, M; Rivera, R; Mahe, E; Carugno, A; Magnano, M; Rech, G; Balogh, E; Feldman, S; De La Cruz, C; Di Meglio, P; Contreras, C; Choon, S; Capon, F; Torres, T; Naldi, L; Weinman, J; Brown, M; Galloway, J; Norton, S; Lambert, J; Spuls, P; Van Huizen, A; Jullien, D; Bachelez, H; Mcmahon, D; Freeman, E; Gisondi, P; Puig, L; Warren, R; Langan, S; Sufka, P; Robinson, P; Yazdany, J; Griffiths, C; Barker, J; Machado, P; Smith, C